Income and corporate franchise tax provisions modified, and addition for pharmaceutical marketing expenses required.

Summary

The bill amends Minnesota tax statutes to treat the federal deduction for direct‑to‑consumer pharmaceutical marketing as an addition, not a deduction, for state income and corporate franchise taxes. It applies to any taxpayer, including drug manufacturers, that claim the deduction under Internal Revenue Code §162. The change becomes effective for taxable years beginning after December 31, 2026.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share